Key Takeaways
- • GSK launches Action Potential Venture Capital (APVC), a $50 million strategic venture capital fund dedicated to bioelectronic medicines and technologies, with SetPoint Medical as the inaugural investment.
- • SetPoint Medical, a California-based developer of implantable devices for treating inflammatory diseases, receives first funding from the newly established APVC fund.
- • GSK's Bioelectronics R&D unit, established in 2012 following a two-year research initiative, underpins the fund's investment strategy and aims to commercialize emerging bioelectronic science.
- • APVC intends to build a portfolio of five to seven portfolio companies between 2013 and 2018, targeting bioelectronic device applications across inflammatory bowel disease, rheumatoid arthritis, asthma, COPD, and Type 2 diabetes.
- • Bioelectronic medicines are designed as miniaturized implantable devices that read and modulate electrical signals (action potentials) in the peripheral nervous system to treat diverse disease categories, representing an early-stage but strategically significant therapeutic approach.
Summary
GlaxoSmithKline announced on August 8, 2013, the establishment of Action Potential Venture Capital Limited, a $50 million corporate venture capital fund focused exclusively on bioelectronic medicines and technologies. The fund represents GSK's formal commitment to commercializing an emerging therapeutic category by investing in pioneering companies at the intersection of neuroscience, medical devices, and pharmaceuticals.
SetPoint Medical, headquartered in California, becomes the fund's first portfolio company. The firm specializes in implantable device technologies designed to treat inflammatory diseases through bioelectronic intervention—representing a validation of GSK's thesis that the bioelectronics space warrants significant capital deployment. The APVC fund aims to expand this initial position into a diversified portfolio of five to seven companies through 2018, establishing a structured investment roadmap over a five-year horizon.
The strategic foundation for APVC builds on GSK's Bioelectronics R&D unit, created in 2012 following an intensive two-year period of market research and scientific engagement. The fund's nomenclature—Action Potential Venture Capital—derives from "action potentials," the electrical impulses that propagate along peripheral nerves. GSK's hypothesis centers on designing miniaturized bioelectronic devices capable of reading, modifying, or generating these neural signals to treat broad disease categories including inflammatory bowel disease, rheumatoid arthritis, respiratory diseases (asthma and COPD), and metabolic disorders such as Type 2 diabetes.
The company frames bioelectronic medicines as a fundamentally different therapeutic modality: instead of systemic pharmacological intervention, these implantable devices interface directly with the peripheral nervous system to modulate organ-specific function. GSK acknowledges that bioelectronic medicines represent a nascent scientific field, positioning the $50 million allocation as a strategic bet on early-stage technology maturation. This venture approach allows GSK to access external innovation, collaborate with specialized research teams, and build downstream intellectual property while maintaining portfolio diversification across an emerging therapeutic frontier.
SetPoint Medical, headquartered in California, becomes the fund's first portfolio company. The firm specializes in implantable device technologies designed to treat inflammatory diseases through bioelectronic intervention—representing a validation of GSK's thesis that the bioelectronics space warrants significant capital deployment. The APVC fund aims to expand this initial position into a diversified portfolio of five to seven companies through 2018, establishing a structured investment roadmap over a five-year horizon.
The strategic foundation for APVC builds on GSK's Bioelectronics R&D unit, created in 2012 following an intensive two-year period of market research and scientific engagement. The fund's nomenclature—Action Potential Venture Capital—derives from "action potentials," the electrical impulses that propagate along peripheral nerves. GSK's hypothesis centers on designing miniaturized bioelectronic devices capable of reading, modifying, or generating these neural signals to treat broad disease categories including inflammatory bowel disease, rheumatoid arthritis, respiratory diseases (asthma and COPD), and metabolic disorders such as Type 2 diabetes.
The company frames bioelectronic medicines as a fundamentally different therapeutic modality: instead of systemic pharmacological intervention, these implantable devices interface directly with the peripheral nervous system to modulate organ-specific function. GSK acknowledges that bioelectronic medicines represent a nascent scientific field, positioning the $50 million allocation as a strategic bet on early-stage technology maturation. This venture approach allows GSK to access external innovation, collaborate with specialized research teams, and build downstream intellectual property while maintaining portfolio diversification across an emerging therapeutic frontier.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.